Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $7.36 million. The enterprise value is -$5.40 million.
Important Dates
The next estimated earnings date is Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 4.75 million shares outstanding.
| Current Share Class | 4.75M |
| Shares Outstanding | 4.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +229.49% |
| Owned by Insiders (%) | 3.87% |
| Owned by Institutions (%) | 7.08% |
| Float | 4.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.13 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.92
| Current Ratio | 6.92 |
| Quick Ratio | 6.85 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -118.88% and return on invested capital (ROIC) is -75.44%.
| Return on Equity (ROE) | -118.88% |
| Return on Assets (ROA) | -52.64% |
| Return on Invested Capital (ROIC) | -75.44% |
| Return on Capital Employed (ROCE) | -75.02% |
| Weighted Average Cost of Capital (WACC) | 3.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.56M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.06% in the last 52 weeks. The beta is -0.13, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -97.06% |
| 50-Day Moving Average | 3.19 |
| 200-Day Moving Average | 9.74 |
| Relative Strength Index (RSI) | 23.77 |
| Average Volume (20 Days) | 1,835,439 |
Short Selling Information
The latest short interest is 27,307, so 0.58% of the outstanding shares have been sold short.
| Short Interest | 27,307 |
| Short Previous Month | 36,688 |
| Short % of Shares Out | 0.58% |
| Short % of Float | 0.60% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.25M |
| Pretax Income | -8.13M |
| Net Income | -14.08M |
| EBITDA | -8.22M |
| EBIT | -8.25M |
| Earnings Per Share (EPS) | -$57.58 |
Full Income StatementBalance Sheet
The company has $12.71 million in cash and n/a in debt, with a net cash position of $12.71 million or $2.68 per share.
| Cash & Cash Equivalents | 12.71M |
| Total Debt | n/a |
| Net Cash | 12.71M |
| Net Cash Per Share | $2.68 |
| Equity (Book Value) | 11.00M |
| Book Value Per Share | 12.27 |
| Working Capital | 10.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.05 million and capital expenditures $17,689, giving a free cash flow of -$10.03 million.
| Operating Cash Flow | -10.05M |
| Capital Expenditures | 17,689 |
| Free Cash Flow | -10.03M |
| FCF Per Share | -$2.11 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
